Top 5 Biosimilars Articles of the Week of October 31


Hello, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of October 31, 2022.

Issue 5: Ivo Abraham, PhD, Matrix45’s chief scientist and professor at the University of Arizona, explored whether biosimilars should be considered a commodity and whether drug commodification is sustainable as the market continues to grow. develop.

Number 4: A report from Cardinal Health indicates that rheumatologists are more familiar with and more confident in biosimilars compared to 2020, showing that education efforts are working and rheumatologists are more willing to prescribe biosimilars to their patients. patients.

Issue 3: The authors of a systematic review have summarized the results of 21 published studies on the efficacy, safety and cost-benefit of trastuzumab biosimilars in growth factor receptor 2 positive breast cancer epidermal (HER2).

Number 2: Similis Bio has signed a license and co-development agreement with Blau Farmacêutica, allowing the latter to have exclusive rights to develop and market 4 biosimilar active ingredients in Latin America.

Number 1: Genentech and Roche have voluntarily recalled their ophthalmology biobetter, Susvimo, an ocular implant for ranibizumab injection, in the United States for a possible leak issue.

To read all of these articles and more, visit


Comments are closed.